Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose chemotherapy with autologous stem cell transplantation vs standard chemotherapy in neoadjuvant triple negative breast cancer
2013-001226-25Phase 2Active
- Sponsor
- ASST Cremona
- Start
- Dec 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin, cyclophosphamide, docetaxel and thiotepa in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by ASST Cremona. Primary endpoint: Pathologic complete response (pCR). Started Dec 2014; status: active.
02
Drugs
epirubicincyclophosphamidedocetaxelthiotepa
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2013-001226-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001226-25.